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Abstract
Autism spectrum disorder (ASD) is a range of neurodevelopmental conditions that are sharply increasing in prevalence
worldwide. Intriguingly, ASD is often accompanied by an array of systemic aberrations including (1) increased serotonin,
(2) various modes of gastrointestinal disorders, and (3) inflammatory bowel disease (IBD), albeit the underlying cause for
such comorbidities remains uncertain. Also, accumulating number of studies report that the gut microbial composition
is significantly altered in children with ASD or patients with IBD. Surprisingly, when we analyzed the gut microbiota of
poly I:C and VPA-induced mouse models of ASD, we found a distinct pattern of microbial dysbiosis that highly
recapitulated those reported in clinical cases of ASD and IBD. Moreover, we report that such microbial dysbiosis
led to notable perturbations in microbial metabolic pathways that are known to negatively affect the host,
especially with regards to the pathogenesis of ASD and IBD. Lastly, we found that serum level of serotonin is
significantly increased in both poly I:C and VPA mice, and that it correlates with increases of a bacterial genus
and a metabolic pathway that are implicated in stimulation of host serotonin production. Our results using
animal model identify prenatal environmental risk factors of autism as possible causative agents of IBD-related
gut microbial dysbiosis in ASD, and suggest a multifaceted role of gut microbiota in the systemic pathogenesis
of ASD and hyperserotonemia.
Introduction
Autism spectrum disorder (ASD) is characterized by
core deficits in neurodevelopmental milestones. How-
ever, a majority of children with ASD also suffer from a
wide range of systemic aberrations such as increased
serum serotonin (40% prevalence) [1–3], gastrointestinal
(GI) distress (up to 90%) [4], and inflammatory bowel
disease (IBD) [5]. Unfortunately, the causative agent for
those conditions and their relationship with etiology and
pathogenesis of ASD remains undefined.
Gut microbiota carries a central role in the health
status of its host via regulation of immune system and
metabolism [6]. Intuitively, one of the most directly
affected host site by microbial dysbiosis is the GI tract,
in that dysbiosis is responsible for the development of
GI disorders and IBD [7]. Gut microbiota is also able
to affect the host’s neurodevelopmental status via gut-
brain-axis [8]. Importantly, a recent paper demon-
strated that administration of beneficial bacteria can
ameliorate a subset of behavioral abnormalities in a
mouse model of autism [9]. Moreover, gut microbiota
profoundly impacts host serotonin production [10], an
imbalance of which leads to GI discomfort and
altered mental status [11].
Co-occurrence of two or more mutually exclusive,
etiologically unrelated diseases is rare; therefore, the fact
that GI disorders and IBD are so prevalent among
children with ASD is highly suggestive of a common
cause for the behavioral abnormalities and systemic
aberrations in ASD. Accordingly, accumulating number
of studies report that the gut microbial composition and
several microbial metabolic pathways are significantly
altered in children with ASD [12, 13] as well as patients
with IBD [14, 15].
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The rising global incidence of ASD [16] implies that
environmental factors might be a contributing compo-
nent in its etiology. We therefore hypothesized that
environmental risk factors are responsible for the gut
microbial dysbiosis in ASD, and that such dysbiosis is a
driving force for the wide range of systemic aberrations
in ASD. To test this, we chose prenatal injection of poly-
inosinic:polycytidylic acid (poly I:C) and valproic acid
(VPA) as our model, which represent two of the most
widely utilized environmental risk factors of ASD. We
analyzed the overall composition of gut microbiota in
poly I:C and VPA mice as well as the relative
abundances of 259 microbial taxa and compared the
results to existing reports on microbial dysbiosis in clin-
ical cases of ASD and IBD. We also performed network
analysis to examine the correlation between microbial
families, and applied the relative abundance data to
metabolic pathway database in order to assess how
microbial dysbiosis might affect the host’s metabolic
system in ASD. Lastly, we tested if ASD mice also
display hyperserotonemia, another highly occurring
comorbidities in ASD.
Methods
Generation of environmental risk factor-induced mouse
models of autism
Pregnant C57BL/6 mice from Japan SLC, Inc. (Japan)
were purchased via Central Lab. Animal Inc. (Seoul,
Korea) and housed in animal biosafety level 2 SPF
facility at Seoul National University College of Medicine,
Korea, with ad libitum supply of standard chow and
water. At embryonic day 12.5 (E12.5), a total of 15
pregnant dams were intraperitoneally injected with poly
I:C (20 mg/kg; Sigma-Aldrich, USA), valproic acid
(VPA) (500 mg/kg; Sigma-Aldrich, USA), or equivalent
amount of saline (5 dams per group). The pups were
weaned at three weeks after birth and were supplied
with the same kind of chow and water. Only male pups
were used for all subsequent experiments.
Behavioral assay
Poly I:C and VPA offspring were subjected to behavioral
assays relevant to autism phenotype at six weeks of age.
The mice were first tested for anxiety-related behavior
using open field chamber (42*42*42 cm), in which
exploratory behavior in a novel environment was
assessed in 10-minute sessions. Locomotor activity was
captured with a video camera and analyzed with Ethovi-
sion XT software (Noldus, USA). The amount of total
movement during the experimental session as well as
time spent in the center region (30*30 cm area) was
measured and compared to corresponding control
(CTL) group.
The mice were also tested for social interaction behavior
using 3-chamber assay [9]. Briefly, testing mice were
habituated for 10 min in the chamber; then two
cylindrical cages were placed on each side of the chamber,
one of which contained a stranger (mouse of the same sex
and age raised in a separate cage), thus testing for social
preference over the non-social cue. 10 min after the initial
interaction, a second stranger mouse was placed in the
empty cage and the behavior of the testing mouse was
again recorded for 10 min, which represents a preference
for a novel social cue. The relative time spent on each
cylindrical cage during each experimental phase was
calculated and compared to that of CTL mice.
Serum serotonin measurement
Blood samples were collected from submandibular veins
of mother and offspring mice by using Goldenrod Animal
Lancet (Braintree Scientific, Inc., USA) according to the
manufacturer’s instructions. Serum was separated from
whole blood by allowing the blood to clot at room
temperature, then centrifuging at 1,000 x g for 10 minutes
at 4 °C. The resulting serum supernatant was then stored
in −20 °C until use. Serum levels of serotonin were mea-
sured using commercial ELISA assay (Eagle Biosciences,
USA) according to the manufacturer’s instructions, and
values from poly I:C and VPA groups were compared to
the corresponding CTL groups of the same age in both
mother and offspring mice.
DNA extraction and Illumina sequencing of mouse fecal
DNA
Fecal samples from mother and offspring mice were
collected at indicated time points and immediately
placed in liquid nitrogen. DNA was extracted from feces
using QIAamp DNA Stool Mini Kit according to the
manufacturer’s instruction (Qiagen, USA), and stored in
−20 °C until use. The fecal DNA samples were PCR-
amplified using Illumina-adapted universal primers
515 F and 806R that target the V4 region of the 16S
rRNA gene [17], and the amplicons were quantified with
the KAPA Library Quantification Kit (KAPA Biosystems,
USA). The resulting amplicons from each sample were
sequenced using the MiSeq platform (Illumina, USA),
which yielded 16S rRNA data for further analysis.
16S rRNA gene sequence processing and statistical
analysis
16S data from mice fecal DNA were processed and
analyzed using QIIME 1.8 software package [18]. First,
the sequences were clustered into operational taxonomic
units (OTUs) at 97% identity using OTU-picking
protocol, and the relative abundances of microbial taxa
from genus to kingdom were generated from non-
rarefied OTU table. Alpha-diversity indexes (PD index,
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Shannon diversity index) were estimated and tested for
significant differences between CTL and poly I:C or
VPA groups using Monte Carlo permutations. Beta-
diversity using unweighted UniFrac distance was calcu-
lated onto a rarefied OTU table, which was grouped into
either timing of sampling or drug treatment.
To evaluate the co-occurrence relationships between
microbial taxa, we calculated Spearman’s ranked
correlation of their relative abundances, and the
networks of co-occurring taxa were then visualized
using Cytoscape [19, 20]. Each node represents a
microbial family (e.g., Prevotellaceae) and the nodes
were paired when their q-values and p-values were
both below 0.05, respectively. The length of the linkage
is proportional to the closeness of the two families.
Microbial functions from the 16S data were predicted
by using PICRUSt [21] and collapsing the predicted
functions into higher categories according to Kyoto
Encyclopedia of Genes and Genomes (KEGG) orthol-
ogy as previously described [22], and the resulting
functioning profiles were visualized as a heatmap using
R package [23].
Statistical significance of differences between CTL and
poly I:C or VPA groups in each experiment were
calculated using either R or Microsoft Excel 2013 using
paired t-test. Differences between groups were deter-
mined significant at *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001.
Results
ASD mice have reduced gut bacterial diversity
According to previous literature on generating environ-
mental risk factor-induced ASD model, we intraperito-
neally injected pregnant C57BL/6 mice with 20 mg/kg
poly I:C [9, 24] or 500 mg/kg VPA [25] at embryonic
day 12.5 (E12.5). When subjected to a battery of stand-
ard behavioral testing at six weeks of age, both poly I:C
and VPA offspring, hereafter referred to as ASD mice,
showed autism-related behavioral abnormalities includ-
ing increased anxiety and decreased social behavior
(Additional file 1: Figure S1).
We analyzed the composition of fecal microbiota of
post-weaned postnatal day 21 (P21) mice, and
observed that the overall composition of gut microbes
of ASD mice did not significantly differ from that of
CTL mice at the phylum level, except for a slight
increase in Firmicutes accompanied by a roughly
equal amount of decrease in Bacteroidetes (Fig. 1a).
On the other hand, analysis of two alpha-diversity
indexes (PD index and Shannon index) showed that
ASD mice harbor significantly less diverse microbial
species (Figs. 1b and c), which is in line with previous
findings in children with ASD [13].
Dietary change, but not poly I:C or VPA, induces beta-
diversity shifts in mice
Beta-diversity index measures the compositional difference
of microbial community between experimental groups
[26], and denotes if a general shift in the microbial com-
munity occurred in response to a stimulus, which in this
case was ASD induction. We analyzed fecal samples from
CTL and ASD mice right before weaning at P21, and twice
more in one-week intervals (P28, P35). Unweighted beta-
diversity analysis showed that as the mice went through
dietary change from mother’s milk (P21) to standard chow
(P28, P35), their gut microbiota experienced a distinguish-
able shift in their composition (Fig. 1d). However, in each
of those time points, the microbial communities of ASD
mice were not clearly distinguished from that of CTL mice
(Fig. 1e). Collectively, the gut microbiota of ASD mice was
not distinguishable from that of CTL mice at the phylum
level or in their general composition; rather, these results
suggest that the decrease in their alpha-diversity indexes
might stem from dysbiosis at the genus or species level.
ASD- and IBD-related gut bacterial species are altered in
ASD mice
A number of studies have reported that children with ASD
[12, 13, 27–29] or patients with IBD [15, 30–39] have al-
tered gut microbial composition at the genus or species
level, some of which are consistently reported across a
number of clinical studies (summarized in Table 1).We
therefore performed relative abundance analysis of gut
microbiota of ASD mice at various taxonomic levels ran-
ging from phylum to species, and found that prenatal
injection of poly I:C and VPA resulted in significant
changes in specific microbial taxa in a pattern that highly
recapitulates those of clinical ASD and IBD (Fig. 2). Both
poly I:C and VPA mice showed significant increases in bac-
terial species that are abundant in ASD (Fig. 2a) or IBD
(Fig. 2b), including Enterococcus [40], which has been sus-
pected to have a causal relationship with the disease pro-
gression of IBD. ASD mice also had significantly less
abundant species that are decreased in clinical IBD (Fig. 2c),
and in the case of Desulfovibrio, both the children with
ASD and Crohn’s disease patients had increased abundance
of the genus, a pattern also observed in ASD mice (Fig. 2d).
Lastly, ASD mice had decreased abundance of Oscillospira
sp., F. Prausnitzii, and Prevotella—all of which are under-
represented in clinical cases of ASD and IBD (Fig. 2d).
Comprehensive lists of microbial taxa significantly altered
in poly I:C and VPA mice are provided in the online ver-
sion of this manuscript (Additional file 4: Table S1).
Prevotellaceae family is significantly and independently
decreased in ASD mice
Out of the 259 microbial taxa tested, the genus Prevotella
showed the most prominent change compared to CTL,
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with statistical significance well below p < 0.0001
(Fig. 2d) in both poly I:C and VPA mice. When we rea-
nalyzed the gut microbial abundance at the family level,
Prevotellaceae comprised more than 7% of the total gut
microbial community in CTL mice, whereas it only
spanned ~2.5% in ASD mice, with many specimens
showing close to zero percentage abundances (Fig. 3a).
We then performed co-occurrence analysis based on
Spearman’s rank correlations to study how microbial
families were interlinked (Fig. 3b), and found that
families such as Rikenellaceae, Peptoccaceae, and
Lactobacillaceae were significantly correlated to more
than dozen other families, indicating that as the abun-
dances of those families change, so do the abundances
of other dozen families. However, Prevotellaceae was
negatively correlated to only four other families—Rike-
nellaceae, Lachnospiraceae, Anaeroplasmataceae, and
Peptostreptococcaceae; moreover, when we applied
weight to the co-occurrence data so that closely linked
families will be shown as such, Prevotellaceae was
Fig. 1 Gut microbial composition and diversity indexes in ASD mice. a Gut microbial composition comparison at the phylum level. b PD index
and c Shannon index of alpha-diversity in CTL and ASD mice. *p < 0.05 vs. CTL. Beta-analysis of CTL and ASD mice shown by d timing of feces
sampling or e drug treatment. n = 9–14 in all experiments
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shown to be separated from all the other families by a
great margin (Fig. 3c). This result suggests that
dysbiosis in other families is not likely to have caused
a noticeable shift in the abundance of Prevotellaceae,
and vice versa. Taken together, the decrease in Prevotella,
which has been reported in clinical cases of both ASD and
IBD, is highly unlikely to have been brought forth by
alterations in other microbial communities in our mouse
model, but more likely by an inhospitable host environ-
ment due to ASD induction.
Metabolic pathways implicated in ASD and IBD are altered
in KEGG pathway analysis of poly I:C and VPA mice
We have thus far examined how ASD induction by
environmental risk factors leads to clinically-relevant
microbial dysbiosis in the offspring. Consequently, we
sought to get an insight of how microbial dysbiosis in turn
affects the metabolism of ASD mice. We assessed the
functional potential of each experimental groups by
applying the 16S data into Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway abundances [22]. As a
result, we found that many pathways that have previously
been implicated in ASD (dioxin degradation [41], steroid
hormone biosynthesis [42]) were altered in the same
manner in ASD mice (Fig. 4a, Table 2), as well as those
implicated in IBD (sulfur metabolism [43], N-Glycan
biosynthesis; [44] Table 2). Notably, lipopolysaccharide
(LPS) biosynthesis and bacterial toxin have been implicated
in the pathogenesis of both ASD [45] and IBD; [46]
accordingly, our results showed that both poly I:C and
VPA mice have significant up-regulations in pathways
involving LPS biosynthesis and bacterial toxins (Fig. 4a).
Comprehensive lists of metabolic pathways significantly al-
tered in poly I:C and VPA mice are provided in the online
version of this manuscript (Additional file 5: Table S2).
ASD mice have elevated level of serum serotonin
Interestingly, we observed one pathway that was up-
regulated in VPA (p = 0.047) and poly I:C mice (p =
0.055), which was not directly implicated in the disease
progression of either ASD or IBD: “Protein digestion
and absorption (hsa04974)”. Nevertheless, this pathway
was of potential interest in that it is implicated in the
production of short chain fatty acids (SCFAs), which are
known to stimulate serotonin production from enterochro-
maffin cells [47]. Elevated serum serotonin, along with GI
disorders and IBD, is another highly occurring comorbidity
in ASD [3]. Importantly, a recent publication has shown
that the gut microbes are responsible for stimulating host
serotonin production, and noted that spore-forming bac-
teria of Clostridia class are responsible for such action.
We therefore analyzed the relative abundance of
Clostridia class bacteria in ASD mice and found that Clos-
tridiales Tissierellaceae Sporanaerobacter, a genus that
forms spores and produces SCFAs [48], was significantly
increased in both poly I:C and VPA mice (Fig. 4b). The in-
crease in SCFA-producing pathway in KEGG analysis, as
well as the increased abundance of spore-forming, acetic-
acid producing bacteria Sporanaerobacter, indicated that
serum serotonin might be increased in these mice as well.
Indeed, when we analyzed the serum from ASD mice, we
observed a significant increase of serum serotonin level
compared to CTL mice (Fig. 4c), a phenomenon not previ-
ously reported in poly I:C and VPA mice models of ASD.
Taken together, our results show that microbial
dysbiosis induced by prenatal poly I:C and VPA treat-
ment not only recapitulated many aspects of microbial
dysbiosis in clinical ASD and IBD, but may also have
functional properties that affect the host’s health status
via alterations in metabolism and serotonin production.
Discussion
Autism spectrum disorder (ASD) now affects approxi-
mately 1 in 161 children globally [16], and is continuing
to rise in prevalence especially in developed countries.
Moreover, children with ASD are commonly burdened
with various gastrointestinal (GI) disorders [4] ranging
from mild GI discomfort and constipation [49] to
inflammatory bowel disease (IBD). Numerous studies
have also reported significant alterations in the compos-
ition of gut microbes in ASD children burdened with GI
Table 1 Bacterial taxa reported as altered in clinical cases of
ASD and IBD
Bacteria vs. HC Reference
ASD-related taxa Dorea sp. ↑ [12]
Parabacteroides ↑ [28]
Desulfovibrio ↑ [28]
Oscillospira sp. ↓ [12]
F. Prausnitzii ↓ [12]
Prevotella ↓ [12] [13],
IBD-related taxa Bilophila ↑ [30]
Enterococcus ↑ [32]
Megasphaera ↑*** [33]
Bacteroides ovatus ↑ [34]
Peptostreptococcaceae ↑** [35]
Coriobacteriaceae ↓*, ** [50]
P. distasonis ↓ [78]
Erysipelotrichaceae ↓* [36]
Desulfovibrio ↑** [37]
Oscillospira sp. ↓* [38]
F. prausnitzii ↓* [79]
Prevotella ↓ [15]
Bold taxa are reported to be altered in both ASD and IBD. The asterisks
(*, **, and ***) next to the arrows denote alterations reported in Crohn’s
Disease, ulcerative colitis, and irritable bowel syndrome, respectively
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disorders [12, 13, 28, 29], the dysbiosis of which is highly
responsible for the development of GI disorders and
IBD [7]. Approximately 40% of children with ASD also
have elevated level of serotonin [2, 3], which might cause
diarrhea and even altered mental status [11]. In this ani-
mal model study, we showed that modeling two environ-
mental risk factors of autism —prenatal injection of poly
I:C or valproic acid (VPA)—results in a distinct pattern
of gut microbial dysbiosis that highly recapitulates those
observed in children with ASD or patients with IBD
(Fig. 2). We have also observed that ASD mice have gut
microbial dysbiosis with decreased alpha-diversity com-
pared to CTL mice, which is in line with few previous
publications on gut microbial profiling of children with
ASD [13] or patients with IBD [14]. This suggests that
prenatal events could act as causal agents for microbial
alteration responsible for IBD [50, 51], one of the most
common comorbidities observed in ASD.
Fig. 2 Relative abundances of gut microbial taxa in ASD mice. Relative abundances of microbial taxa in CTL and ASD mice. The data are divided with
respect to the pattern of dysbiosis reported in previous clinical studies on either children with ASD or patients with IBD. a Taxa reported to have been
significantly a increased in children with ASD or b patients with IBD. c Taxa that are decreased in patients with IBD. d Taxa that are increased (Desulfovibrio)
or decreased (Prevotella, F. prausnitzii, Oscillospira) in both ASD and IBD. Asterisks next to taxa names denote the statistical significance of the difference
between CTL and each ASD experimental group. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 vs. CTL. n = 9-14 in all experiments
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Our result on IBD-like microbial dysbiosis in two
environmental risk factor models of ASD adds support
to previous studies that have investigated how prenatal
injection of poly I:C or VPA affects the GI tract in off-
spring later in life. Similar to patients with IBD [52], poly
I:C offspring exhibit GI barrier defects such as increased
permeability, and abnormal expression of tight junction
proteins in the gut [9]. In addition, poly I:C offspring
display significantly elevated level of plasma cytokines
such as IL-2, IL-5, and IL-6 [53]. As for VPA, male VPA
offspring have been shown to display epithelial loss in
the ileum as well as signs of neutrophil infiltration in
their gut [54], a phenomenon frequently observed in
clinical cases of IBD [55, 56]. Prenatal VPA injection in
rats resulted in reduced thickness of the mucosa and
muscle layers of GI tract in the offspring, which was
accompanied by significant changes in the morphologies
of GI epithelial cells such as atrophy, weak cytoplasm
staining, and distracted arrangement of chief cells;
moreover, the GI transit index was significantly
decreased in the VPA offspring, indicating functional
deficit of GI in response to prenatal VPA injection [57].
Taken together, previous studies have shown that pre-
natal administration of environmental risk factors of
ASD can induce IBD-like symptoms in the offspring,
and thereby suggest possible connection between ASD
and IBD at the tissue level.
Out of the 259 taxa tested, the most prominently and
uniquely altered taxa was Prevotella, a fermenter of plant
polysaccharides. For this reason, it has been suggested
that decrease in Prevotella in the intestine might be
associated with various digestive disorders [13]. Accord-
ingly, clinical reports have shown that Prevotella is
significantly decreased in both autistic individuals [13]
Fig. 3 Prevotellaceae family is significantly and independently altered in ASD mice. a Relative abundance of Prevotellaceae in ASD mice compared to
CTL mice. P values were calculated against CTL group. b Unweighted co-occurrence network analysis of gut microbial families in ASD mice.
c Co-occurrence network weighted with linkage strength. Red and blue lines denote positive and negative correlation, respectively
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and IBD patients [15], indicating that changes in the
relative abundance of Prevotella might be a key factor
that links ASD and IBD. Prevotella has also recently
attracted attention due to its distinct pattern of abun-
dance in response to diet, in that it is highly prevalent in
rural Africa and significantly reduced in the Western
world [58], the latter of which harbors countries with
one of the most highest incidence of ASD [16]. Notably,
our present results bring a new insight to the relation-
ship between ASD and Prevotella, in that prenatal envir-
onmental risk factors of ASD may render the host’s
enteric environment inhospitable for the growth of
Prevotella, an effect which seems to have overcome the
controlled dietary environment in our study setting. It
would be of potential value to test if colonization of
Prevotella or administration of prebiotics aimed at
increasing its prevalence might alter the inflammatory
status of ASD mice or even its behavioral abnormalities.
We also showed that microbial dysbiosis is likely to
affect the host’s health status via alteration of its meta-
bolic pathways (Fig. 4a). A variety of metabolic distur-
bances has been reported in ASD [41, 42, 59–65] and
Fig. 4 Possible metabolic perturbations caused by microbial dysbiosis in ASD mice. a KEGG pathway analysis based on 16S data drawn out in
heatmap. All pathways except “Protein digestion and absorption” have significant (p < 0.05) differences between CTL and each ASD experimental
group. In “Protein digestion and absorption”, the p-values of CTL vs. VPA and CTL vs. Poly I:C are 0.045 and 0.055, respectively. Pathways in the
red box have been reported to be perturbed in children with ASD, and those in the blue box have been implicated in patients with IBD. Purple
box denotes that ASD and IBD showed the same manner of alteration in those pathways. b Relative abundance analysis of Sporanaerobacter
in CTL and ASD mice. *p < 0.05 vs. CTL. c Serotonin level in serum detected by ELISA in CTL and ASD mice. *p < 0.05 vs. CTL. n= 9-14 in all experiments
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IBD [43, 51, 66–69], with a possible relationship to the
etiology or progression of those conditions. One
example is the elevated level of lipopolysaccharide (LPS)
and bacterial endotoxins: in ASD, an elevation of
circulating level of bacterial endotoxin in ASD patients
compared to healthy controls (HCs) was reported [45],
and it was repeatedly demonstrated in murine models
that early life exposure to LPS results in ASD-like behav-
ioral abnormalities via inflammatory responses [70, 71].
With regards to IBD, endotoxemia was also reported in
a major subset of patients with ulcerative colitis or
Crohn’s disease [46], as well as serum markers of LPS
exposure in pediatric IBD patients [66]. Interestingly,
ASD mice also showed an elevated level of metabolic
pathways associated with LPS: “Lipopolysaccharide bio-
synthesis”, “Lipopolysaccharide biosynthesis proteins”, and
“Bacterial toxins” (Fig. 4a, purple box). Accordingly, one
research group hypothesized that toxin-producing harm-
ful gut bacterial species such as Desulfovibrio might con-
tribute to ASD [29], and later reported that Desulfovibrio
was found more frequently in the stools of autistic
children compared to HCs [28]. Similarly, we also
observed that the relative abundance of Desulfovibrio is
significantly increased in both poly I:C and VPA mice
(Fig. 2d). Taken together, our results link poly I:C- and
VPA-induced microbial dysbiosis with endotoxemia impli-
cated in both ASD and IBD, thereby lending more support
to the microbial basis of ASD etiology and pathogenesis.
Hyperserotonemia in autistic individuals was first
reported more than fifty years ago [72], and has been
continued to be described in major subsets of autistic
children to the point that researchers have suggested
elevated serum serotonin as a possible cause or aggrava-
tor of ASD-like behavioral phenotypes [1, 3]. One study
also proposed that serotonin pathway can be utilized as
a biomarker for autism diagnosis [2], although the
underlying cause for such aberration remained unclear.
Recently, expression of a variant in serotonin transport
gene (SLC6A4) in mice was shown to result in hyperser-
otonemia and ASD-related behavioral abnormalities
[73]. However, no single genetic variant or mutation
related to ASD accounts for more than 1-2% of the total
affected population [74], a figure falling far short of the
prevalence of hyperserotonemia (40%). Instead, we here
report for the first time that modeling environmental
risk factors of ASD in mice resulted in a significantly
elevated level of serum serotonin (Fig. 4c), and that it is
accompanied by alterations in bacterial metabolic path-
way related to the production of SCFAs, which are
known inducers of serotonin production [47]. We also
show that the rise in serum serotonin was accompanied
by an increased abundance of Sporanaerobacter of
Clostridia class, a genus that forms spores and produces
SCFAs [48]. This genus carries relevance in that a recent
publication, through the use of germ-free mice, has skill-
fully demonstrated the role of spore-forming bacteria on
the production of serotonin [10]. Thus, our results suggest
that the widespread prevalence of hyperserotonemia in
children with ASD might have a microbial basis.
In our study, it is possible that the metabolism and gut
microbial status of the pre-weaned pups was largely
affected by their mothers, possibly through milk inges-
tion. However, whereas Prevotellaceae was significantly
reduced in the feces of offspring (Fig. 3a), the same
phenomenon was not observed in the feces of their
mothers (Additional file 2: Figure S2). Also, whereas
serum from offspring right before weaning showed
significantly increased amount of serotonin (Fig. 4c),
their mothers did not show any statistically significant
increase in their serum serotonin at any time point
(Additional file 3: Figure S3). These results argue against
the possibility that the mothers were the primary target
of poly I:C and VPA injection in terms of microbial
dysbiosis and hyperserotonemia.
A few papers have argued that the gut microbial com-
position of children with ASD do not differ significantly
from those of HCs or siblings [75, 76]. The apparent
discordances among microbiota studies on ASD children
might stem from differences in sampling and sequencing
methods or cohort designation regarding autism severity
and the presence of GI disorders. Nevertheless, mount-
ing clinical evidence shows that children with ASD do
suffer from various GI disorders and IBD [4, 61, 77], and
since microbial dysbiosis accounts for a significant part
Table 2 Metabolic pathways implicated in clinical cases of ASD
and IBD
Pathway vs. HC Reference
ASD-related
pathways
LPS/LPS proteins/Bacterial toxins ↑ [45]
Steroid hormone biosynthesis ↑ [42]
Ion channels/Pores ion channels ↑ [59]
Inorganic ion transport and
metabolism
↑ [60]
Cell motility and secretion ↑ [61]
Xylene degradation ↓ [63]
Transporters ↓ [64]
Dioxin degradation ↓ [41]
Electron transfer carriers ↓ [65]
IBD-related
pathways
LPS/LPS proteins/Bacterial toxins ↑ [46]
Sulfur metabolism ↑ [43]
Glycosaminoglycan degradation ↑ [67]
Geraniol degradation ↑ [68]
N-Glycan biosynthesis ↑ [44]
Benzoate degradation ↓ [51]
Ether lipid metabolism ↓ [69]
Bold pathways are reported to be altered in both ASD and IBD
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of the etiology of those conditions [7], gut microbiota in
ASD warrants further study with a focus on adjusting
for the high degree of inter-individual variability.
Microbiota as a research area is complex and rapidly
growing, and its apparent involvement in ASD calls for
targeted investigation of its relationship with the
pathogenesis of the disorder. Our present study using
animal model shows that (1) prenatal exposure to
environmental risk factors is able to alter the abun-
dances of many gut microbial taxa later in life, and that
(2) such dysbiosis carries the possibility of directly
affecting the host’s health status via metabolic changes
and serotonin pathway. Future research might benefit
from focusing on the role of Prevotella in ASD and
IBD, or describing in detail how ASD and IBD cause
significant decreases in its abundance. We also suggest
that poly I:C and VPA mouse are promising models for
studying microbial dysbiosis in ASD, which might aid
in developing a therapeutic regimen for ASD and/or
IBD based on microbial manipulation.
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